Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-29

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective observational trial of patients with metastatic cancer of various entities which aims at both clarifying the significance of liquid biopsy and establishing a foundation for translational research.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer

NCT05708599

Non-Small-Cell Lung Carcinoma Colorectal Cancer Pancreatic Ductal Adenocarcinoma

ACTIVE_NOT_RECRUITING NA

Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma

NCT04490564

Head and Neck Squamous Cell Carcinoma Non Small Cell Lung Cancer Melanoma

COMPLETED

Liquid Biopsy of Head and Neck Cancer Patients in Blood and Saliva

NCT05122507

Head and Neck Squamous Cell Carcinoma

UNKNOWN

Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT)

NCT06367751

Advanced Solid Tumor

RECRUITING NA

Liquid Biopsy in Mature B-cell Tumors

NCT03280394

Mature B-Cell Neoplasm

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ALPS is a prospective observational trial to assess liquid biopsy as diagnostic tool in patients with various metastatic neoplasms. Liquid biopsy will be correlated not only with the tissue biopsy, but also to imaging modalities and classical tumor markers. In addition, the study aims to investigate clonal heterogeneity and evolution of different cancers during patient treatment courses. A third aspect of the study is to survey and assess patients' knowledge about biomarkers and personalized medicine in general and about liquid biopsy as a new diagnostic tool.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Characteristics Disease Metastatic Cancer Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Age ≥ 18 years
* Histopathologically confirmed metastatic or locally advanced cancer
* No curative treatment options, except for germ cell tumors
* Written Agreement to be followed up at Augsburg University Medical Center
* Signed written informed consent for the Biobank Augsburg (Biobank-A)
* Willing to undergo treatment according to standard of care
* Availability or anticipated availability of tumor tissue at time point of inclusion
* Anticipated life expectancy of at least 3 months at time point of trial inclusion